Skip to contentBVF PARTNERS L P/IL — ARENA PHARMACEUTICALS INC insider: 308 transactions · InsiderLensBVF PARTNERS L P/IL
- See Remarks at CELL THERAPEUTICS INC · on record since Jun 28, 2023
- Former 10% Owner at Therapeutics Acquisition Corp. · on record since Dec 20, 2023
- 10% owner at enGene Holdings Inc. · on record since Nov 13, 2023
- 10% owner at Therapeutics Acquisition Corp. · on record since Nov 6, 2023
- See Remarks; Former 10% Owner at Rain Enhancement Technologies Holdco, Inc. · on record since Jan 29, 2024
- 10% owner at Allakos Inc. · on record since Jan 26, 2024
- 10% owner at Xenon Pharmaceuticals Inc. · on record since Sep 12, 2016
- See Explanation of Responses at TF FINANCIAL CORP · on record since Oct 31, 2024
- See Explanation of Responses at PALVELLA THERAPEUTICS, INC. · on record since Dec 17, 2024
- See Explanation of Responses at 4D Molecular Therapeutics, Inc. · on record since Nov 13, 2024
- See Explanation of Responses at Olema Pharmaceuticals, Inc. · on record since Dec 4, 2024
- See Explanation of Responses at KENT FINANCIAL SERVICES INC · on record since Dec 28, 2011
- Director at IMMUNIC, INC. · on record since Feb 27, 2026
- See Explanation of Responses at IMMUNIC, INC. · on record since Feb 27, 2026
- Director at Rain Enhancement Technologies Holdco, Inc. · on record since May 25, 2021
- 10% owner at DYNAVAX TECHNOLOGIES CORP · on record since Jul 29, 2009
- 10% owner at ADOLOR CORP · on record since Sep 24, 2009
- 10% owner at CREATIVE VISTAS INC · on record since Jul 11, 2003
- 10% owner at ARQULE INC · on record since Sep 21, 2009
- 10% owner at TARGACEPT INC · on record since Jul 16, 2009
- 10% owner at FIRST ALBANY COMPANIES INC · on record since Sep 10, 2009
- 10% owner at NEUROGEN CORP · on record since Jul 17, 2003
- Indirect Beneficial Owner at NEUROGEN CORP · on record since Jul 17, 2003
- 10% owner at MEDICINOVA INC · on record since Dec 24, 2009
- 10% owner at COMBINATORX, INC · on record since Dec 24, 2009
- 10% owner at NEUROBIOLOGICAL TECHNOLOGIES INC /CA/ · on record since Oct 23, 2009
- 10% owner at AVIGEN INC \DE · on record since Oct 23, 2009
- Indirect Beneficial Owner at ARQULE INC · on record since Jul 22, 2003
- 10% owner at NEUROCRINE BIOSCIENCES INC · on record since Mar 29, 2010
- 10% owner at ADVANCED MAGNETICS INC · on record since Jul 29, 2003
- Indirect Beneficial Owner at ADVANCED MAGNETICS INC · on record since Jul 29, 2003
- 10% owner at SUPERGEN INC · on record since Apr 21, 2010
- 10% owner at Celera CORP · on record since Mar 23, 2011
- Director at MoonLake Immunotherapeutics · on record since Apr 2, 2026
- 10% owner at MoonLake Immunotherapeutics · on record since Apr 2, 2026
- 10% owner at GENAERA CORP · on record since Sep 5, 2003
- 10% owner at CAPRIUS INC · on record since Jun 29, 2011
- 10% owner at LIGAND PHARMACEUTICALS INC · on record since Aug 22, 2011
- 10% owner at ICAGEN INC · on record since Sep 9, 2011
- 10% owner at ARRAY BIOPHARMA INC · on record since Dec 5, 2011
- 10% owner at PALATIN TECHNOLOGIES INC · on record since Oct 7, 2011
- 10% owner at ARENA PHARMACEUTICALS INC · on record since Oct 21, 2003
- Indirect Beneficial Owner at ARENA PHARMACEUTICALS INC · on record since Oct 21, 2003
- 10% owner at BIOCRYST PHARMACEUTICALS INC · on record since Oct 29, 2003
- Indirect Beneficial Owner at BIOCRYST PHARMACEUTICALS INC · on record since Oct 29, 2003
- See Explanation of Responses at NEUROCRINE BIOSCIENCES INC · on record since Feb 10, 2012
- Indirect Beneficial Owner at ARRAY BIOPHARMA INC · on record since Nov 7, 2003
- 10% owner at DISCOVERY PARTNERS INTERNATIONAL INC · on record since Dec 30, 2016
- 10% owner at ChemoCentryx, Inc. · on record since Aug 31, 2012
- Indirect Beneficial Owner at APPLIED MOLECULAR EVOLUTION INC · on record since Jan 6, 2004
- 10% owner at APPLIED MOLECULAR EVOLUTION INC · on record since Jan 6, 2004
- 10% owner at RIGEL PHARMACEUTICALS INC · on record since May 15, 2013
- 10% owner at XOMA LTD /DE/ · on record since May 18, 2026
- 10% owner at Oncothyreon Inc. · on record since Jun 7, 2013
- See Explanation of Responses at LIGAND PHARMACEUTICALS INC · on record since Mar 26, 2014
- See Explanation of Responses at Regado Biosciences Inc · on record since Mar 25, 2014
- 10% owner at Regado Biosciences Inc · on record since Feb 10, 2014
- 10% owner at ZONAGEN INC · on record since Feb 18, 2004
- Indirect Beneficial Owner at ZONAGEN INC · on record since Feb 18, 2004
- See Explanation of Responses at Oncothyreon Inc. · on record since Jul 16, 2014
- See Explanation of Responses at TARGACEPT INC · on record since Aug 21, 2015
- 10% owner at CELL THERAPEUTICS INC · on record since Dec 14, 2015
- See Explanation of Responses at ChemoCentryx, Inc. · on record since Nov 5, 2015
- 10% owner at NOVELLUS SYSTEMS INC · on record since Jun 22, 2017
- 10% owner at INSITUFORM TECHNOLOGIES INC · on record since Jan 28, 2005
- Indirect Beneficial Owner at INSITUFORM TECHNOLOGIES INC · on record since Jan 28, 2005
- 10% owner at GLYCOMIMETICS INC · on record since May 11, 2017
- 10% owner at CONCERT PHARMACEUTICALS, INC. · on record since Sep 29, 2017
- See Explanation of Responses at CAPRIUS INC · on record since Jul 18, 2017
- 10% owner at Regulus Therapeutics Inc. · on record since Nov 27, 2017
- 10% owner at Syndax Pharmaceuticals Inc · on record since Dec 8, 2017
- 10% owner at PALVELLA THERAPEUTICS, INC. · on record since Nov 26, 2018
- 10% owner at Immune Design Corp. · on record since Nov 9, 2018
- 10% owner at Calithera Biosciences, Inc. · on record since Jul 1, 2019
- 10% owner at FIVE PRIME THERAPEUTICS INC · on record since Oct 31, 2019
- 10% owner at CYTOKINETICS INC · on record since Dec 12, 2019
- 10% owner at Merus N.V. · on record since Jan 21, 2020
- 10% owner at IDEAYA Biosciences, Inc. · on record since Jun 22, 2020
- Director at XOMA LTD /DE/ · on record since Aug 25, 2020
- 10% owner at Principia Biopharma Inc. · on record since Aug 20, 2020
- See Explanation of Responses at Tokai Pharmaceuticals Inc · on record since Dec 28, 2020
- 10% owner at CytomX Therapeutics, Inc. · on record since Dec 28, 2020
- Director at Olema Pharmaceuticals, Inc. · on record since Nov 20, 2020
- 10% owner at Olema Pharmaceuticals, Inc. · on record since Nov 20, 2020
- See Explanaton of Responses at CYTOKINETICS INC · on record since Nov 20, 2020
- See Explanaton of Responses at FIVE PRIME THERAPEUTICS INC · on record since Nov 13, 2020
- 10% owner at Tokai Pharmaceuticals Inc · on record since Oct 5, 2020
- See Explanation of Responses at DISCOVERY PARTNERS INTERNATIONAL INC · on record since Feb 19, 2021
- See Explanation of Responses at CytomX Therapeutics, Inc. · on record since Feb 18, 2021
- Director at CELL THERAPEUTICS INC · on record since Mar 12, 2021
- See Explanation of Responses at IDEAYA Biosciences, Inc. · on record since Feb 4, 2021
- 10% owner at Repare Therapeutics Inc. · on record since Nov 8, 2021
- 10% owner at Cullinan Therapeutics, Inc. · on record since Jan 10, 2022
- 10% owner at Verastem, Inc. · on record since Feb 7, 2022
- 10% owner at 4D Molecular Therapeutics, Inc. · on record since Jun 27, 2022
- 10% owner at EPIX Pharmaceuticals, Inc. · on record since Jul 21, 2022
- 10% owner at TF FINANCIAL CORP · on record since Dec 22, 2022
- Director at Kymera Therapeutics, Inc. · on record since Jan 13, 2023
- See Remarks and Footnotes at Kymera Therapeutics, Inc. · on record since Jan 13, 2023
- 10% owner at Structure Therapeutics Inc. · on record since Feb 13, 2023
- See Remarks at XOMA LTD /DE/ · on record since Jan 9, 2023
Insider trading activity of BVF PARTNERS L P/IL
- Transactions on record
- 308
- since Jul 29, 2003
- Open-market buys
- 167
- $30.1M
- Open-market sells
- 96
- $73M
- Companies traded
- 31
- last filing Jun 26, 2026
Figures computed from official regulatory filings — methodology.
Companies where BVF PARTNERS L P/IL has traded
- Kymera Therapeutics, Inc.11 tx · $4.2M · Jun 26, 2026
- Olema Pharmaceuticals, Inc.1 tx · Jun 23, 2026
- MoonLake Immunotherapeutics4 tx · $63M · Jun 22, 2026
- XOMA LTD /DE/19 tx · $23M · May 18, 2026
- Repare Therapeutics Inc.3 tx · Jan 30, 2026
- CELL THERAPEUTICS INC2 tx · Apr 7, 2023
- IDEAYA Biosciences, Inc.3 tx · $835.4K · Feb 4, 2021
- Principia Biopharma Inc.3 tx · $81.2K · Aug 20, 2020
- DISCOVERY PARTNERS INTERNATIONAL INC8 tx · $6.5M · Jun 21, 2018
Track record of BVF PARTNERS L P/IL
Statistical track record
Free- Open-market buys
- 170
- Last buy
- May 27, 2022
Win rates and median returns are available with a free account (5 insiders/month).
Create a free account→Transaction history of BVF PARTNERS L P/IL
Co-insiders of BVF PARTNERS L P/IL
This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →
15 tx · $8.5M · Apr 6, 2018
| Company | Filed | Type | Qty | Price | Value · USD | Src |
|---|
| Jun 26, 2026 | Sell | -837,914 | 106.50 USD | — | SEC |
| Jun 26, 2026 | Sell | -51,858 | 106.50 USD | — | SEC |
| Jun 26, 2026 | Sell | -113,289 | 106.50 USD | — | SEC |
| Jun 26, 2026 | Sell | -627,597 | 106.50 USD | — | SEC |
| Jun 25, 2026 | AwardD | 6,068 | 0.00 USD | — | SEC |
| Jun 23, 2026 | AwardD | 29,500 | 0.00 USD | — | SEC |
| Jun 22, 2026 | AwardD | 22,195 | 0.00 USD | — | SEC |
| May 18, 2026 | Other | 772,000 | 4.03 USD | $3.1M | SEC |
| May 18, 2026 | Other | 2,313,000 | 4.03 USD | $9.3M | SEC |
| May 18, 2026 | Other | 1,506,000 | 4.03 USD | $6.1M | SEC |
| May 18, 2026 | OtherD | -1,506 | 0.00 USD | $0 | SEC |
| May 18, 2026 | OtherD | -772 | 0.00 USD | $0 | SEC |
| May 18, 2026 | Other | 412,000 | 4.03 USD | $1.7M | SEC |
| May 18, 2026 | OtherD | -2,313 | 0.00 USD | $0 | SEC |
| May 18, 2026 | OtherD | -412 | 0.00 USD | $0 | SEC |
| Apr 2, 2026 | Sell | -1,569,116 | 16.79 USD | $26.3M | SEC |
| Apr 2, 2026 | Sell | -1,932,354 | 16.79 USD | $32.4M | SEC |
| Apr 2, 2026 | Sell | -248,530 | 16.79 USD | $4.2M | SEC |
| Jan 30, 2026 | Other | -5,309,432 | — | — | SEC |
| Jan 30, 2026 | Other | -4,308,573 | — | — | SEC |
| Jan 30, 2026 | Other | -548,938 | — | — | SEC |
| May 19, 2023 | AwardD | 10,967 | 0.00 USD | $0 | SEC |
| Apr 7, 2023 | AwardD | 80,000 | 0.00 USD | $0 | SEC |
| May 31, 2022 | Buy | 10,642 | 14.21 USD | $151.2K | SEC |
| May 31, 2022 | Buy | 90,372 | 14.21 USD | $1.3M | SEC |